These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 10495795)
1. Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration. Gaspari F; Anedda MF; Signorini O; Remuzzi G; Perico N J Am Soc Nephrol; 1997 Apr; 8(4):647-52. PubMed ID: 10495795 [TBL] [Abstract][Full Text] [Related]
2. A limited sampling strategy for the estimation of eight-hour neoral areas under the curve in renal transplantation. Meier-Kriesche HU; Kaplan B; Brannan P; Kahan BD; Portman RJ Ther Drug Monit; 1998 Aug; 20(4):401-7. PubMed ID: 9712465 [TBL] [Abstract][Full Text] [Related]
3. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients? Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945 [TBL] [Abstract][Full Text] [Related]
4. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. International Neoral Renal Transplantation Study Group. Am J Transplant; 2002 Feb; 2(2):148-56. PubMed ID: 12099517 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery. Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413 [TBL] [Abstract][Full Text] [Related]
6. Dose adjustment strategy for oral microemulsion formulation of cyclosporine: population pharmacokinetics-based analysis in kidney transplant patients. Tokui K; Kimata T; Uchida K; Yuasa H; Hayashi Y; Itatsu T; Nabeshima T Ther Drug Monit; 2004 Jun; 26(3):287-94. PubMed ID: 15167630 [TBL] [Abstract][Full Text] [Related]
7. A limited sampling strategy for the estimation of 12-hour SangCya and neoral AUCs in renal transplant recipients. Meier-Kriesche HU; Alloway R; Gaber AO; Canafax DM; Kaplan B J Clin Pharmacol; 1999 Feb; 39(2):166-71. PubMed ID: 11563409 [TBL] [Abstract][Full Text] [Related]
8. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Canadian Neoral Renal Transplantation Study Group Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295 [TBL] [Abstract][Full Text] [Related]
10. A limited sampling strategy for the estimation of 12-hour Neoral systemic drug exposure in heart transplant recipients. Balram C; Sivathasan C; Cheung YB; Tan SB; Tan YS J Heart Lung Transplant; 2002 Sep; 21(9):1016-21. PubMed ID: 12231373 [TBL] [Abstract][Full Text] [Related]
11. Limited sampling model for area-under-the-curve monitoring in pediatric patients receiving either Sandimmune or Neoral cyclosporin A oral formulations. Medeiros M; Pérez-Urizar J; Muñoz R; Castañeda-Hernández G Pediatr Transplant; 1999 Aug; 3(3):225-30. PubMed ID: 10487284 [TBL] [Abstract][Full Text] [Related]
12. Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients. Kelles A; Herman J; Tjandra-Maga TB; Van Damme-Lombaerts R Pediatr Transplant; 1999 Nov; 3(4):282-7. PubMed ID: 10562972 [TBL] [Abstract][Full Text] [Related]
13. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation]. Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420 [TBL] [Abstract][Full Text] [Related]
14. A limited sampling strategy for the estimation of 12-hour cyclosporine neoral area under the curve in Chinese cardiac transplant recipients. Wang CH; Ko WJ; Chou NK; Wang SS Transplant Proc; 2004 Oct; 36(8):2390-2. PubMed ID: 15561259 [TBL] [Abstract][Full Text] [Related]
15. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Mahalati K; Belitsky P; Sketris I; West K; Panek R Transplantation; 1999 Jul; 68(1):55-62. PubMed ID: 10428267 [TBL] [Abstract][Full Text] [Related]
16. Abbreviated pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporine therapy in de novo renal transplant patients treated with Sandimmune or Neoral. Neoral study group. Marsh CL Ther Drug Monit; 1999 Feb; 21(1):27-34. PubMed ID: 10051051 [TBL] [Abstract][Full Text] [Related]
17. A polycaprolactone nanoparticle formulation of cyclosporin-A improves the prediction of area under the curve using a limited sampling strategy. Molpeceres J; Chacón M; Guzmán M; Berges L; del Rosario Aberturas M Int J Pharm; 1999 Sep; 187(1):101-13. PubMed ID: 10502617 [TBL] [Abstract][Full Text] [Related]
18. A limited sampling strategy for the estimation of Neoral AUCs in pediatric patients. Meier-Kriesche HU; Bonilla-Felix MA; Ferris ME; Swinford R; Kahan BD; Brannan P; Portman RJ Pediatr Nephrol; 1999 Nov; 13(9):742-7. PubMed ID: 10603112 [TBL] [Abstract][Full Text] [Related]
19. Limited sampling strategy for cyclosporine (Neoral) area under the curve monitoring in pediatric kidney transplant recipients. Strong DK; Lai A; Primmett D; White CT; Lirenman DS; Carter JE; Hurley RM; Virji M; Ensom MH Pediatr Transplant; 2005 Oct; 9(5):566-73. PubMed ID: 16176411 [TBL] [Abstract][Full Text] [Related]
20. Cyclosporine monitoring in patients with renal transplants: two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure. Primmett DR; Levine M; Kovarik JM; Mueller EA; Keown PA Ther Drug Monit; 1998 Jun; 20(3):276-83. PubMed ID: 9631924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]